EOLS | Evolus, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	10.64 - 10.95
52 Week Range	9.80 - 17.82
Beta	1.09
Implied Volatility	75.76%
IV Rank	73.80%
Day's Volume	277,300
Average Volume	605,528
Shares Outstanding	63,321,500
Market Cap	687,038,275
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2018-02-08

Valuation
Profitability
Growth
Health
P/E Ratio	-11.92
Forward P/E Ratio	N/A
EPS	-0.91
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	322
Country	USA
Website	EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS's peers: ALKS, AMPH, AMRX, ASRT, VNRX, COLL, PAHC, ANIP, PROC, SSIC, EGRX, DCPH, PBH, PCRX, ITCI, AAWH, IXHL, SUPN, OPTN

*Chart delayed

Analyzing fundamentals for EOLS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see EOLS Fundamentals page.

Watching at EOLS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EOLS Technicals page.